Comparing the current results to its competitors, Edgewise Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.28 %, recorded in the same quarter.
Edgewise Therapeutics inc , slower than the average decrease reported by the company's competitors of -4.83 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -4.83 %
Edgewise Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape for emerging treatments for hypertrophic cardiomyopathy (HCM) includes several companies developing cardiac myosin inhibitors (CMIs). Bristol-Myers Squibb markets Camzyos (mavacamten), which is approved in the US, Europe, and other countries. Cytokinetics has received FDA approval and a positive opinion from the EMA for aficamten. Other companies involved in developing therapies targeting symptomatic obstructive HCM (oHCM) in patients with NYHA class II-III include Imbria Pharmaceuticals, Lexicon Pharmaceuticals, Celltrion, and Braveheart Bio. The company utilizes trade secrets, patents, and proprietary information to maintain its competitive position but acknowledges risks related to protecting such information. Additionally, pharmaceutical products may face competition from lower-priced products in foreign countries with price controls and imported foreign products, as well as challenges related to reimbursement and healthcare reform.
Publicly Traded Peers of Edgewise Therapeutics inc
Forte Biosciences Inc Share Performance
+226.09%
This Year
Forte Biosciences Inc
Profile
Forte Biosciences Inc is a biotechnology company focused on developing and commercializing innovative solutions for the treatment of dermatological diseases. Their business model centers around researching, developing, and bringing to market products that address unmet needs in the field of skin health through their proprietary technology platform.
Grifols SA operates a business model that focuses on plasma-derived medicine production and commercialization, including plasma collection, testing, and fractionation, as well as the development of diagnostic equipment and transfusion medicine. Their core activities involve the extraction of plasma, transforming it into life-saving therapies, and distributing them worldwide to healthcare providers.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of innovative drugs. Their business model revolves around identifying potential drug targets, conducting research and preclinical studies to validate these targets, and subsequently developing drugs through clinical trials for various therapeutic areas. They also collaborate with pharmaceutical companies for joint development and commercialization efforts, aiming to bring these drugs to market and improve patient outcomes.
Sources:
Edgewise Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Edgewise Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
